Publicaciones en colaboración con investigadores/as de University of Toronto (49)

2024

  1. Anxious and depressive symptoms and health-related quality of life in a cohort of people who recently attempted suicide: A network analysis

    Journal of Affective Disorders, Vol. 355, pp. 210-219

  2. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods

    Scientific Reports, Vol. 14, Núm. 1

  3. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  4. Impact of mediterranean diet promotion on environmental sustainability: a longitudinal analysis

    Public Health, Vol. 230, pp. 12-20

  5. The Human Phenotype Ontology in 2024: phenotypes around the world

    Nucleic acids research, Vol. 52, Núm. D1, pp. D1333-D1346

2023

  1. A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo

    Science translational medicine, Vol. 15, Núm. 697, pp. eadf4549

  2. Exploratory study of ultraviolet B (UVB) radiation and age of onset of bipolar disorder

    International Journal of Bipolar Disorders, Vol. 11, Núm. 1

  3. Health financing policies during the COVID-19 pandemic and implications for universal health care: a case study of 15 countries

    The Lancet Global Health, Vol. 11, Núm. 12, pp. e1964-e1977

  4. Modular adjuvant-free pan-HLA-DR-immunotargeting subunit vaccine against SARS-CoV-2 elicits broad sarbecovirus-neutralizing antibody responses

    Cell Reports, Vol. 42, Núm. 4

2022

  1. Association between polarity of first episode and solar insolation in bipolar I disorder

    Journal of Psychosomatic Research, Vol. 160

  2. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 7

  3. Engineering pan-HIV-1 neutralization potency through multispecific antibody avidity

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 119, Núm. 4

2021

  1. Exploring risk and resilient profiles for functional impairment and baseline predictors in a 2-year follow-up first-episode psychosis cohort using latent class growth analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 1, pp. 1-20

  2. Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile

    iScience, Vol. 24, Núm. 9

  3. Identifying clinical clusters with distinct trajectories in first-episode psychosis through an unsupervised machine learning technique

    European Neuropsychopharmacology, Vol. 47, pp. 112-129

  4. Longitudinal changes in adherence to the portfolio and DASH dietary patterns and cardiometabolic risk factors in the PREDIMED-Plus study

    Clinical Nutrition, Vol. 40, Núm. 5, pp. 2825-2836

  5. Lyophilized, thermostable Spike or RBD immunogenic liposomes induce protective immunity against SARS-CoV-2 in mice

    Science Advances, Vol. 7, Núm. 49

  6. Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease

    Scientific Reports, Vol. 11, Núm. 1

  7. Multivalency transforms SARS-CoV-2 antibodies into ultrapotent neutralizers

    Nature Communications, Vol. 12, Núm. 1

  8. Trajectories of suicidal ideation after first-episode psychosis: a growth mixture modeling approach

    Acta psychiatrica Scandinavica, Vol. 143, Núm. 5, pp. 418-433